Advancing leptomeningeal metastases treatment in EGFR-mutated non-small cell lung cancer: lessons from the BLOSSOM trial

被引：0
|
作者：
Bortolot, Martina [1 ,2 ]
Huijs, Jarno W. J. [1 ]
Brandsma, Dieta [3 ]
Compter, Annette [3 ]
van Geel, Robin M. J. M. [4 ,5 ]
Hendriks, Lizza E. L. [1 ]
机构：
[1] Maastricht Univ, Med Ctr, GROW Res Inst Oncol & Reprod, Dept Pulm Dis, P Debyelaan 25,POB 5800, NL- 6202 AZ Maastricht, Netherlands
[2] Univ Udine, Dept Med DMED, Udine, Italy
[3] Netherlands Canc Inst Antoni Leeuwenhoek, Dept Neurooncol, Amsterdam, Netherlands
[4] Maastricht Univ, Med Ctr, Dept Clin Pharm & Toxicol, Maastricht, Netherlands
[5] Maastricht Univ, Cardiovasc Res Inst Maastricht CARIM, Maastricht, Netherlands
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2025年 / 14卷 / 01期
关键词：
Non-small cell lung cancer (NSCLC); leptomeningeal metastases (LM); epidermal growth factor receptor (EGFR); osimertinib; BLOSSOM trial; OSIMERTINIB; ERLOTINIB; NSCLC;
D O I：
10.21037/tlcr-24-1006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：7 / 13
页数：7
相关论文
共 50 条
  • [1] Progression of leptomeningeal metastases in advanced EGFR-mutated non-small cell lung cancer
    Zhao, Q.
    Deng, L.
    Zhang, Y.
    Zhou, X.
    Li, Y.
    Yu, M.
    Zhou, L.
    Zou, B.
    Liu, Y.
    Lu, Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Leptomeningeal carcinomatosis from EGFR-mutated non-small cell lung cancer
    Iuchi, T.
    Shingyoji, M.
    Setoguchi, T.
    Yoshida, Y.
    Ashinuma, H.
    Hasegawa, Y.
    Sakaida, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series
    Li, Huiying
    Yu, Tingting
    Huang, Mingmin
    Guo, Aibin
    Qian, Xiaoping
    Yin, Zhenyu
    ONCOTARGETS AND THERAPY, 2019, 12 : 7785 - 7790
  • [4] Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer
    Bhandari, Shruti
    Dunlap, Neal
    Kloecker, Goetz
    JOURNAL OF THORACIC DISEASE, 2021, 13 (05) : 3230 - 3234
  • [5] Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
    Chen, H.
    Wang, L.
    Wu, Y.
    Wu, Y.
    Ma, S.
    Sen, Y.
    Zhen, H.
    Mo, Y.
    Zhang, C.
    Wang, Q.
    ANNALS OF ONCOLOGY, 2023, 34 : S1697 - S1697
  • [6] Treatment strategy of EGFR-mutated non-small cell lung cancer
    Tanaka, Fumihiro
    Yoneda, Kazue
    Takenaka, Masaru
    Kuroda, Koji
    JOURNAL OF THORACIC DISEASE, 2022, 14 (03) : 602 - 606
  • [7] Systemic treatment of EGFR-mutated non-small cell lung cancer
    Czyzykowski, Rafal L.
    Wrona, Ewa K.
    Talajko, Agata
    Hasinska, Aleksandra M.
    Potemski, Piotr J.
    ONCOLOGY IN CLINICAL PRACTICE, 2024,
  • [8] EGFR-mutated non-small lung cancer brain metastases and radiosurgery outcomes with a focus on leptomeningeal disease
    Alzate, Juan Diego
    Mullen, Reed
    Mashiach, Elad
    Bernstein, Kenneth
    Vasconcellos, Fernando De Nigris
    Rotmann, Lauren
    Berger, Assaf
    Qu, Tanxia
    Silverman, Joshua S.
    Golfinos, John G.
    Donahue, Bernadine R.
    Kondziolka, Douglas
    JOURNAL OF NEURO-ONCOLOGY, 2023, 164 (02) : 387 - 396
  • [9] EGFR-mutated non-small lung cancer brain metastases and radiosurgery outcomes with a focus on leptomeningeal disease
    Juan Diego Alzate
    Reed Mullen
    Elad Mashiach
    Kenneth Bernstein
    Fernando De Nigris Vasconcellos
    Lauren Rotmann
    Assaf Berger
    Tanxia Qu
    Joshua S. Silverman
    John G. Golfinos
    Bernadine R. Donahue
    Douglas Kondziolka
    Journal of Neuro-Oncology, 2023, 164 (2) : 387 - 396
  • [10] Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors
    Saboundji, Karima
    Auliac, Jean-Bernard
    Perol, Maurice
    Francois, Geraldine
    Janicot, Henri
    Marcq, Marie
    Dubos-Arvis, Catherine
    Renault, Aldo
    Guisier, Florian
    Odier, Luc
    Gervais, Radj
    Chouaid, Christos
    TARGETED ONCOLOGY, 2018, 13 (04) : 501 - 507
12345